Oncolytic virotherapy needs trials, not access programs.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23549877.
- Also identified by DOI 10.1158/1078-0432.CCR-13-0571.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oncolytic virotherapy is a novel treatment for cancer that exerts direct lytic and indirect immune-mediated antitumor effects. A Finnish research team has reported on an advanced therapy access program for oncolytic adenovirus. The strengths and weaknesses of this approach are highlighted with a view to informing future study conduct.
Medical subject headings
- Neoplasms
- Oncolytic Virotherapy
- T-Lymphocytes